MARKET

RDY

RDY

Dr Reddys Labs
NYSE
69.76
-0.07
-0.10%
After Hours: 70.22 +0.46 +0.66% 16:07 12/05 EST
OPEN
69.77
PREV CLOSE
69.83
HIGH
69.92
LOW
69.32
VOLUME
163.88K
TURNOVER
0
52 WEEK HIGH
73.17
52 WEEK LOW
50.75
MARKET CAP
11.61B
P/E (TTM)
18.96
1D
5D
1M
3M
1Y
5Y
Weekly Report: what happened at RDY last week (1127-1201)?
Weekly Report · 1d ago
Amneal Pharma in pact with Strides to launch generic Vascepa
Amneal pharmaceuticals in pact with strides to launch generic version of amarin's heart disease drug vascepa. Icosapent ethyl capsules will be sold in the u.s. By the end of this year. Generic drugmakers dr. Reddy's, teva and hikma also manufacture copycat versions of the drug.
Seeking Alpha · 4d ago
Dr Reddys Labs: Report of foreign issuer
Press release · 4d ago
Dr. Reddy's Laboratories: Q2 Earnings Reveals Strong Growth And Promising Advancements
Dr. Reddy's laboratories reports strong growth in their india, north america, europe, and emerging markets businesses. The company reported record-breaking sales and profitability in their q2 2024 earnings report. Dr. Redy's focuses on innovation, geographic diversification, and responsible corporate practices.
Seeking Alpha · 6d ago
Dr Reddys Labs: Report of foreign issuer
Press release · 11/28 15:06
Weekly Report: what happened at RDY last week (1120-1124)?
Weekly Report · 11/27 09:06
Dr Reddys Labs: Report of foreign issuer
Press release · 11/21 17:05
Dr Reddys Labs: Report of foreign issuer
Press release · 11/20 12:04
More
About RDY
Dr. Reddy’s Laboratories Limited is an India-based global pharmaceutical company. The Company offers a portfolio of products and services, including active pharmaceutical ingredients (APIs), generics, branded generics, biosimilars and over-the-counter (OTC). Its major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. The Company’s segments include Pharmaceutical Services and Active Ingredients, Global Generics, and Others. The Pharmaceutical Services and Active Ingredients segment primarily consists of the Company’s business of manufacturing and marketing APIs and intermediates. The Global Generics segment consists of the Company’s business of manufacturing and marketing prescription and OTC finished pharmaceutical products ready for consumption by the patient, marketed under a brand name (branded formulations) or as generic finished dosages with therapeutic equivalence to branded formulations (generics).

Webull offers Dr Reddy's Laboratories Ltd (ADR) stock information, including NYSE: RDY real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, RDY stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading RDY stock methods without spending real money on the virtual paper trading platform.